Direkt zum Inhalt
Merck
  • Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.

Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.

Antimicrobial agents and chemotherapy (2007-08-08)
Sonia K Morgan-Linnell, Lynn Zechiedrich
ZUSAMMENFASSUNG

In defined, isogenic strains, at least three mutations, two of which must be in gyrA, were required to exceed the CLSI breakpoint for fluoroquinolone resistance. Strains with double mutations in both gyrA and parC had even higher MICs of fluoroquinolones than strains with totals of three mutations.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Sigma-Aldrich
Sparfloxacin, ≥98.0% (HPLC)
Supelco
Norfloxacin, analytical standard, ≥98% (TLC)
Supelco
Ciprofloxacin, VETRANAL®, analytical standard
Supelco
Norfloxacin, VETRANAL®, analytical standard